EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line

Rheumatoid arthritis is a chronic inflammatory autoimmune disease characterized by symmetrical polyarthritis, leading to progressive joint destruction and functional disability. Early and effective intervention with disease-modifying antirheumatic drugs is essential to alter the disease course. For decades, methotrexate has been the anchor drug in RA treatment due to its established efficacy, acceptable safety profile, and cost-effectiveness.¹ Despite the growing range of therapies, EULAR 2026 presentations consistently affirmed the enduring relevance of MTX as the preferred initial csDMARD.²

The clinical dilemma often revolves around optimizing MTX initiation, dose escalation, and combination strategies to maximize treatment response while minimizing adverse events. Current guidelines from the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR) recommend MTX as the first-line csDMARD, often in combination with short-term glucocorticoids.^3,4 But variability in real-world practice regarding initial dosing and escalation schedules persists.⁵

Optimizing Methotrexate in First-Line RA

Rapid dose escalation and subcutaneous administration maximize methotrexate efficacy in early rheumatoid arthritis. A meta-analysis of 14 randomized controlled trials (N=4,870) confirmed methotrexate monotherapy beats placebo for ACR20 response with an odds ratio of 3.2 (95% CI: 2.5-4.1, p<0.001).⁶ Studies initiating methotrexate at 10 to 15 mg/week and escalating to 20 to 25 mg/week within 4 to 8 weeks yielded a 42% remission rate (DAS28-CRP <2.6) at 6 months, compared to 28% for slower regimens (P=.003).⁷

Route of administration and combination strategies offer additional optimization levers. A prospective observational cohort of 850 patients with early disease showed subcutaneous methotrexate above 15 mg/week reduced gastrointestinal discontinuation compared to oral dosing (HR 0.68, 95% CI: 0.52-0.89, P=.005).⁸ For patients at risk of oral intolerance, this route facilitates reaching target doses and improving treatment persistence.⁸ In a 620-patient head-to-head trial, triple therapy (methotrexate, sulfasalazine, hydroxychloroquine) produced a non-significant ACR50 increase at 12 months versus monotherapy (58% vs 51%, P=.08).⁹ But patients with baseline erosions or anti-CCP positivity saw a clear benefit from triple therapy, achieving a 65% ACR50 rate versus 48% (P=.02).⁹ This reinforces the current guideline recommendation to consider combination csDMARDs in patients with indicators of more aggressive disease.³

These optimization trials do not establish a universal escalation protocol for patients with baseline hepatic impairment or severe renal dysfunction. The meta-analysis excluded patients with baseline transaminase elevations, leaving a gap in how to safely push doses in populations with metabolic dysfunction. The 6-month and 12-month endpoints capture early response but fail to document whether rapid escalation prevents radiographic progression at year 5. The triple therapy data relies on clinical endpoints without providing matched MRI data to confirm structural preservation.

Clinicians must default to rapid dose escalation while monitoring the well-established safety profile of methotrexate. Liver enzyme elevations (ALT >3x ULN) occurred in approximately 5 to 10% of patients, typically transient and reversible upon dose reduction or temporary cessation.¹⁰ Myelosuppression remained rare, occurring in less than 1% of patients, emphasizing the importance of regular laboratory monitoring.¹⁰ Practice should shift from conservative oral dosing to rapid escalation, switching to subcutaneous delivery at the first sign of gastrointestinal distress to maintain the therapeutic dose.

Short-Term Endpoints Obscure Long-Term Transition Timing

The current evidence base fails to define the optimal timing for transitioning non-responders to biologic therapies. The EULAR 2026 data draws heavily from interim analyses and specific cohorts that do not reflect the diverse comorbidities seen in daily practice. Heterogeneity in patient populations and treatment protocols across these studies complicates direct comparisons. Clinicians lack a standardized definition of treatment failure that dictates exactly when to abandon optimized methotrexate.

The congress abstracts present outcomes at 6 and 12 months, tracking early remission rates and initial adverse events. Long-term comparative effectiveness data for various methotrexate escalation strategies and combination regimens in diverse real-world settings remains scarce. The absence of extensive follow-up data forces clinicians to extrapolate from shorter studies. This carries a risk of underestimating long-term adverse events or overestimating sustained remission rates.

The presented evidence does not establish clear biomarkers to predict individual patient response to methotrexate or other conventional synthetic disease-modifying antirheumatic drugs. Without such predictive tools, clinicians rely on a trial-and-error approach. This delays optimal treatment for some patients and risks unnecessary exposure to ineffective therapies. The current data leaves the initial drug selection process entirely empirical, forcing patients to endure months of potential non-response before alternative mechanisms of action are considered under existing guidelines.^3,4

Clinicians should interpret the EULAR 2026 findings as reinforcing aggressive initial dosing rather than solving the problem of non-response. Individual patient factors, comorbidities, and preferences must dictate when to abandon conventional therapy. Ongoing vigilance for adverse events and careful monitoring of disease activity remain essential when applying findings from highly controlled trial settings to the broader patient population. Until biomarker discovery enables personalized management, aggressive dose escalation followed by rapid transition upon failure remains the most practical clinical strategy.

For more detailed insights into the latest evidence-based approaches to rheumatology, including evolving RA treatment protocols, refer to the Oxford Handbook of Rheumatology.